Microtubule inhibitors

9,010views

test

00:00 / 00:00

Microtubule inhibitors

Internal Medicine

Internal Medicine

Blood transfusion reactions and transplant rejection: Pathology review
Immunodeficiencies: Clinical
Antihistamines for allergies
Glucocorticoids
Non-corticosteroid immunosuppressants and immunotherapies
Advanced cardiac life support (ACLS): Clinical
Supraventricular arrhythmias: Pathology review
Ventricular arrhythmias: Pathology review
Heart blocks: Pathology review
Coronary artery disease: Clinical
Heart failure: Clinical
Syncope: Clinical
Pericardial disease: Clinical
Cardiomyopathies: Clinical
Hypertension: Clinical
Hypercholesterolemia: Clinical
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Sympathomimetics: Direct agonists
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Positive inotropic medications
Diabetes mellitus: Clinical
Hyperthyroidism: Clinical
Hypothyroidism and thyroiditis: Clinical
Parathyroid conditions and calcium imbalance: Clinical
Pituitary adenomas and pituitary hyperfunction: Clinical
Hypopituitarism: Clinical
Cushing syndrome: Clinical
Adrenal masses and tumors: Clinical
Adrenal insufficiency: Clinical
MEN syndromes: Clinical
Neuroendocrine tumors of the gastrointestinal system: Pathology review
Hyperthyroidism medications
Hypothyroidism medications
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Adrenal hormone synthesis inhibitors
Mineralocorticoids and mineralocorticoid antagonists
Esophageal disorders: Clinical
Esophagitis: Clinical
Gastroesophageal reflux disease (GERD): Clinical
Gastroparesis: Clinical
Malabsorption: Clinical
Inflammatory bowel disease: Clinical
Jaundice: Clinical
Cirrhosis: Clinical
Laxatives and cathartics
Antidiarrheals
Acid reducing medications
Fever of unknown origin: Clinical
Fat-soluble vitamin deficiency and toxicity: Pathology review
Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review
Anemia: Clinical
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Leukemia: Clinical
Lymphoma: Clinical
Thrombocytopenia: Clinical
Bleeding disorders: Clinical
Thrombophilia: Clinical
Myeloproliferative neoplasms: Clinical
Plasma cell disorders: Clinical
Blood products and transfusion: Clinical
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Infective endocarditis: Clinical
Pneumonia: Clinical
Tuberculosis: Pathology review
Diarrhea: Clinical
Viral hepatitis: Clinical
Urinary tract infections: Clinical
Meningitis, encephalitis and brain abscesses: Clinical
Bites and stings: Clinical
HIV and AIDS: Pathology review
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Hypernatremia: Clinical
Hyponatremia: Clinical
Hyperkalemia: Clinical
Hypokalemia: Clinical
Metabolic and respiratory acidosis: Clinical
Metabolic and respiratory alkalosis: Clinical
Toxidromes: Clinical
Medication overdoses and toxicities: Pathology review
Acute kidney injury: Clinical
Chronic kidney disease: Clinical
Nephritic and nephrotic syndromes: Clinical
Renal tubular defects: Pathology review
Renal tubular acidosis: Pathology review
Environmental and chemical toxicities: Pathology review
Osmotic diuretics
Carbonic anhydrase inhibitors
Loop diuretics
Potassium sparing diuretics
Stroke: Clinical
Seizures: Clinical
Headaches: Clinical
Dementia and delirium: Clinical
Hyperkinetic movement disorders: Clinical
Hypokinetic movement disorders: Clinical
Muscle weakness: Clinical
Disorders of consciousness: Clinical
Spinal cord disorders: Pathology review
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Migraine medications
Anti-parkinson medications
Medications for neurodegenerative diseases
Asthma: Clinical
Chronic obstructive pulmonary disease (COPD): Clinical
Diffuse parenchymal lung disease: Clinical
Venous thromboembolism: Clinical
Acute respiratory distress syndrome: Clinical
Pleural effusion: Clinical
Pneumothorax: Clinical
Lung cancer: Clinical
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Pulmonary corticosteroids and mast cell inhibitors
Joint pain: Clinical
Rheumatoid arthritis: Clinical
Seronegative arthritis: Clinical
Systemic lupus erythematosus (SLE): Clinical
Sjogren syndrome: Clinical
Inflammatory myopathies: Clinical
Vasculitis: Clinical
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Opioid agonists, mixed agonist-antagonists and partial agonists
Antigout medications
Non-biologic disease modifying anti-rheumatic drugs (DMARDs)
Osteoporosis medications

Assessments

Flashcards

0 / 14 complete

USMLE® Step 1 questions

0 / 2 complete

USMLE® Step 2 questions

0 / 3 complete

Flashcards

Microtubule inhibitors

0 of 14 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 2 complete

USMLE® Step 2 style questions USMLE

0 of 3 complete

A 73-year-old man presents to the emergency room with hematuria and generalized fatigue for the past month. The patient has not experienced abdominal pain, fever, dysuria, or increased frequency of micturition. However, he has experienced a 3.5 kg (9 lb) weight loss over the last month and loss of appetite. Family history is noncontributory. He has smoked 2-3 packs of cigarettes daily for the past 30 years. He does not consume alcohol or use recreational substances. Temperature is 37.0°C (98.6°F), pulse is 90/min, respirations are 16/min, and blood pressure is 120/70 mmHg. Physical examination is unremarkable. Urinalysis is shown below. Cystoscopy is performed and biopsy specimens are obtained. Molecular analysis of the cells reveals malignant features and high sensitivity to paclitaxel. Which of the following is the mechanism of action of the most appropriate therapeutic agent?  

Laboratory Value
Result
Color
Clear
Specific gravity  
1.013
Glucose
Negative
Blood
Positive
Leukocyte esterase  
Negative
Nitrites
Negative
Leukocytes
1-2/hpf
Erythrocytes
60/hpf
Dysmorphic RBCs  
Absent
Casts
None

External References

First Aid

2024

2023

2022

2021

Breast cancer

paclitaxel for p. 445

Ovarian cancer

paclitaxel for p. 445

Paclitaxel p. 445

in cell cycle p. 443

microtubules and p. 46

targets of p. 443

Transcript

Watch video only

Microtubule inhibitors, as their name implies, disrupt the microtubules and inhibit mitosis, which is a specific phase of the cell cycle.

Anticancer agents in this class include the vinca alkaloids and the taxanes.

But first things first.

The cytoskeleton is a network of proteins within the cell that gives each cell its shape, and it anchors organelles in place.

But it’s also a dynamic network, which can change shape when the cell wants to move, contract, divide, or pull in or push out molecules.

It’s made up of three proteins: actin filaments, intermediate filaments, and microtubules.

Microtubules are made of alternating round proteins called α- and β-tubulins, which form long strands called protofilaments.

Thirteen of these protofilaments come together to form a single microtubule.

Microtubules play a super important role in cell division.

During cell division there are two centrosomes inside the cell, and each centrosome is made out of two centrioles.

Each centriole is in turn made up of nine sets of microtubule triplets.

Now cell division, or mitosis, can be divided into four subphases: prophase, metaphase, anaphase, and telophase.

During prophase, the membrane around the nucleus disintegrates, and the chromosomes condense.

During metaphase, chromosomes move towards the middle of the cell, on a line called the metaphase plate.

Each chromosome is made up of a pair of sister chromatids which are joined together in the centromere where there’s a specific protein complex called the kinetochore.

When the chromosomes are in place, each centrosome sends out thread-like projections called spindle fibers, that attach to the centromere of each chromosome.

Spindle fibers consist of microtubules that originate from the centrioles and polymerize in the direction of the kinetochores.

Next, during anaphase, the centrosomes start pulling on the spindle fibers to pull the sister chromatids apart, forming the mitotic spindle.

It looks a bit like a fishing line being cast out to its target, and then the line gets reeled in, pulling the kinetochore and it’s attached sister chromatid away from its partner chromosome.

Finally, there’s the telophase during which a nuclear membrane forms around each new set of 46 single-chromatid chromosomes.

After that, during cytokinesis, the cell membrane pinches in until the two daughter cells separate.

Alright, now cancer cells replicate rapidly so they are constantly undergoing mitosis and the microtubules are always at work.

This means that microtubule inhibitors will affect these cells more than our healthy cells, most of which only divide occasionally.

Interfering with the formation of microtubules will cause mitosis to fail and the cell will eventually die without replicating.

The two commonly used anticancer microtubule inhibitors include the vinca alkaloids and the taxanes.

All anticancer microtubule inhibitors are given intravenously.

Okay, let’s start with vinca alkaloids, which include vinblastine, and vincristine.

Vinca alkaloids bind to β-tubulin and block its polymerization into protofilaments, which form microtubules, centrioles, centrosomes, and spindle fibers.

This means the cell can’t form stable mitotic spindles and will stop at metaphase.

So, vinca alkaloids act in the M phase of the cell-cycle and are cell-cycle specific.

Moving on to indications.

Vinca alkaloids are used for solid tumors like: breast cancer; pediatric tumors like rhabdomyosarcoma and nephroblastoma or Wilms tumor; and leukemias.

Now, vincristine and vinblastine are both used for Hodgkin’s and non-Hodgkin’s lymphoma.

Let’s move on to side effects.

Vinca alkaloids disrupt the progression of mitosis in all rapidly dividing cells in the body including hair follicles and gastrointestinal epithelium, so vinblastine and vincristine cause alopecia, or loss of hair, and gastrointestinal symptoms.

In addition, they are associated with bone marrow suppression since the cells here are constantly making the platelets, red, and white blood cells.

Now, vinblastine causes more bone marrow suppression, but vincristine is more neurotoxic as it interferes with microtubule polymerization in neuronal axons disrupting the neuronal activity.

Neurotoxicity usually manifests as peripheral neuropathy causing symptoms like a decrease in sensation in the toes and fingers, sometimes called a glove and stocking distribution, as well as autonomic nervous system malfunction with orthostatic hypotension, urinary retention, and constipation.

Alright, next are the taxanes, which are also alkaloid derivatives, and include paclitaxel and docetaxel.

Taxanes also act on microtubules, but they act differently from vinca alkaloids.

Summary

Microtubules are a component of the cytoskeleton which are involved in cellular transport and cell division. Microtubule inhibitors work by disrupting the function of microtubules, which stops or slows down cell division and movement. This can be useful in cancer treatment, as it can stop or slow down the spread of cancer cells. Some common microtubule inhibitors include paclitaxel (Taxol) and vincristine.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "A microtubule bestiary: structural diversity in tubulin polymers" Molecular Biology of the Cell (2017)
  5. "Cell division: The renaissance of the centriole" Current Biology (1999)
  6. "Cancer Management" UBM Medica (2008)
  7. "Mechanism of taxane neurotoxicity" Breast Cancer (2004)
  8. "Docetaxel" Drugs (2005)